Usman Saeedullah

PGY2 @icahnmountsinai aspiring cardiologist

[Jogun-omi @Omo_Alhaja14]

If your best hat-trick came against Jordan, don’t compare yourself to someone doing it against Spain😂

[Toni Kroos @ToniKroos]

Football won

[Harrison Bonilla @HarrisJBonilla]

Had so much fun presenting my abstract at #NYValves2026! 🫀 Grateful to my mentors and co-authors. Extra motivated heading into fellowship application season! #CardioX #CardioTwitter #MedTwitter #Cardiology #StructuralHeart #MedEd

[🏆💍 @Brungod]

Oh btw Brunson's ring is heavier than both of KD's rings combined

[Game of Thrones @GameOfThrones]

Jalen Brunson,
First of His Name,
Breaker of Double Teams,
King of New York,
Most Valuable Player.

[Nike Basketball @nikebasketball]

Sleep well, NY.

[NEW YORK KNICKS @nyknicks]

Welcome to the Mecca, @jalenbrunson1‼️

[SNY Knicks @sny_knicks]

December 30, 2023.

[Josh Hart @joshhart]

ASSENAL!!!!!

[Nike Basketball @nikebasketball]

You know what’s better than an Eastern Conference Finals MVP?

[ESPN @espn]

WHAT DID WE JUST WITNESS?!? 👽

ALL-TIME LEGENDARY PERFORMANCE FROM WEMBY‼️

[NEJM @NEJM]

Presented at #HRS2026:

In patients with persistent atrial fibrillation, first-line treatment with pulsed field ablation reduced the recurrence of atrial arrhythmias at 12 months as compared with antiarrhythmic drugs. Full AVANT GUARD trial results: https://t.co/milHy26ojJ

@HRSonline

[Usman Saeedullah @usman_sa1]

Amazing experience presenting my research @ACCinTouch 2026 in NOLA. Thank you to my mentors @acamajmd @argulian and Dr. Casso for their continuous support. 🫀⚜️ #acc2026 #cardioX

[American College of Cardiology @ACCinTouch]

Results from the SURVIV study presented during a Late-Breaking Clinical Trial session at #ACC26: mViV vs. rMVR For Mitral Bioprosthetic Valve Dysfunction

Get full details: https://t.co/0vB0iZrxzU #CardioX

[Saad Ur Rahman @SaadUrRahman55]

Summary of all Late-Breaking Trials at #ACC2026 – take home points
@ACCinTouch @ACCmediacenter @JACCJournals

1. HI-PEITHO: Ultrasound-facilitated catheter-directed thrombolysis led to a lower risk of PE-related death, cardiopulmonary decompensation or collapse, or recurrence of PE. vs anticoagulation alone in intermediate-high risk PE.

[Dr. Deepak L. Bhatt @DLBHATTMD]

#cardiology #cardiovascular #cardiotwitter #cardioX

[Mount Sinai Fuster Heart Hospital @MountSinaiHeart]

Speak with Dr. @usman_sa1 at #ACC26 to learn about his latest research in cardiology on left atrial appendage occlusion and myocardial infarction.

#CardioX #Cardiology #Research #MyocardialInfarction @IcahnMountSinai @ACCinTouch @DLBHATTMD

[Ahmed Bennis MD 🫀 @drbennisahmed]

five studies I would put at the top of the ACC.26 March 28–30, 2026, in New Orleans

1.CHAMPION-AF — primary results comparing left atrial appendage closure vs oral anticoagulation in patients with atrial fibrillation.

2.STEMI-Door to Unload — results of primary left ventricular unloading in anterior STEMI without cardiogenic shock

3.Spironolactone in the Treatment of Heart Failure

4.TAVI Without Routine PCI — a randomized trial testing transcatheter aortic valve implantation without routine percutaneous coronary intervention.

5.Discontinuation of β-blocker Therapy in Stabilized Patients After Acute Myocardial Infarction
#ACC26 #Cardiology #MedTwitter #CardioTwitter #HeartHealth #Healthcare

@JACCJournals @ACCinTouch @DrMarthaGulati @hvanspall @BiykemB @ankeetbhatt @ShelleyZieroth @Hragy @cardioceptor

https://t.co/qdUNXUfOEl

[Dr. Chacón-Lozsán F .'. @franciscojlk]

🫀 Vasopressin in Cardiogenic Shock: Are we underusing a key tool?

A recent ESC Heart Failure review provides a comprehensive analysis of vasopressin in cardiogenic shock, covering pathophysiology, clinical evidence, and therapeutic applications.
While traditionally associated with distributive shock, vasopressin may play a crucial role in selected cardiogenic shock phenotypes.

🔍 Key takeaways:
• Cardiogenic shock is a heterogeneous syndrome requiring phenotype-driven therapy
• Vasopressin offers a non-adrenergic mechanism, potentially improving perfusion pressure while reducing catecholamine-related adverse effects
• Particularly relevant in:
– Low SVR / mixed shock states
– Post-cardiac arrest shock
– Tachyarrhythmia-related cardiogenic shock
• Important to recognize scenarios where vasopressin may be detrimental.

🎯 The message is clear:
We should move toward physiology-guided, individualized vasopressor strategies rather than a one-size-fits-all approach.

📖 Highly recommended reading for intensivists and cardiologists managing shock.

ESC Heart Failure (2026) 13, xvag053 https://t.co/s8awez1jKj

#CardiogenicShock #Vasopressin #CriticalCare #Cardiology #Hemodynamics #ESC #ICU